Skip to content

Amlexanox

Also called Aphthasol

Inhibits TBK1 and IKK-epsilon, two kinases that drive the chronic low-grade inflammation of obesity and suppress energy expenditure.

  • TypeSmall molecule
  • FormOral
  • Researched forMetabolic & Fat Loss

Where to get Amlexanox

Disguised Alpha
Oral
Code CAMERON

21+ to enter. The only form sold. Research compound, not approved for human use.

Shop oral at Disguised Alpha

The short version

  • Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
  • What the evidence isFDA-approved — as a 5% oral paste for aphthous ulcers, which has nothing to do with why it appears here.
  • What to watchCold sores, shingles or other viral infections that return or linger.

How Amlexanox works

Amlexanox inhibits two kinases — TBK1 and IKK-epsilon — and the reason that produces a metabolic effect is one of the most satisfying mechanism chains in this catalog, because it ends at a specific enzyme in the fat cell.

The chain, one step at a time. Obesity produces a chronic inflammatory state involving NF-kappaB signaling, and one consequence is persistent elevation of the non-canonical IkappaB kinases IKK-epsilon and TBK1 in white adipose tissue. Those kinases phosphorylate and activate PDE3B, the major adipocyte phosphodiesterase.

Blocking them raises cAMP and increases metabolic rate in fat tissue.

  • Oral

On the goal map: Substrate partitioning & insulin control (Lose fat)

Research on Amlexanox7 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: A small pilot in obese type-2 diabetics improved HbA1c and hepatic fat — in responders only.

Human clinical evidence

  • FDA-approved — as a 5% oral paste for aphthous ulcers, which has nothing to do with why it appears here. That approval establishes human safety by a topical route only.

  • A phase 2 trial in obese patients with type 2 diabetes tested it orally and reported improved glycemic control and reduced hepatic steatosis — but only in a responder subgroup, roughly half the participants, distinguished by their inflammatory profile at baseline.

  • A responder-only result in a small trial is a hypothesis about who it works for, not a demonstration that it works.

Correlative data

  • Almost no metabolic real-world use; it remains largely a research compound outside its dental indication. The trial identified elevated baseline inflammatory markers as the responder signature, which is at least a testable prediction.

How the mechanism reads

  • Inhibits TBK1 and IKK-epsilon, two kinases induced by obesity-related inflammation that suppress energy expenditure by degrading cAMP signaling in fat tissue.

    Mechanistic
  • The interesting claim is directional: these kinases are part of a counter-regulatory brake that switches on with chronic inflammation, so inhibiting them releases a brake rather than pressing an accelerator.

    Mechanistic
  • That explains the responder subgroup precisely — if the brake is not engaged, there is nothing to release. It is one of the few compounds here whose mechanism predicts its own non-responders.

    Mechanistic

Sources

  • Mowers J, et al. Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKepsilon and TBK1. eLife 2013 · PMID 24368730
  • Xiao QA, et al. Role of IKKepsilon in the Metabolic Diseases: Physiology, Pathophysiology, and Pharmacology. Frontiers in Pharmacology 2022 · PMID 35662709
  • Zhao P, et al. The TBK1/IKKepsilon inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis. JCI Insight 2022 · PMID 35917178
  • Huh JY, et al. Roles of IkappaB kinases and TANK-binding kinase 1 in hepatic lipid metabolism and nonalcoholic fatty liver disease. Experimental and Molecular Medicine 2021 · PMID 34848839
  • You W, et al. Unlocking therapeutic potential of amlexanox in MASH with insights into bile acid metabolism and microbiome. NPJ Gut and Liver 2025 · PMID 40519640
  • Hui L, et al. Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease. Clinical and Experimental Immunology 2024 · PMID 39248363

Amlexanox safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Active or recurrent viral infection, or immune suppression, because TBK1 carries antiviral interferon signaling.
  • Liver disease.
  • Type 1 diabetes or insulin use, as its effect on glucose handling is unmapped.
  • Allergy to the drug.
  • Pregnancy or under 18, where immune-kinase blockade is untested.

What’s expected

  • Higher cAMP in fat cells and a modest rise in energy use.
  • Lower inflammatory kinase tone, shown in small diabetes trials as better glucose or liver fat in some people.
  • Nothing noticeable day to day for most people.

Watch for

  • Cold sores, shingles or other viral infections that return or linger.
  • Yellow skin or dark urine.
  • Palpitations with unusual sweating.

Labs that tell you it’s working

  • HbA1c: the diabetes trials used glucose control as the endpoint.
  • Insulin (Fasting): inflammation-driven insulin resistance is the target.
  • hs-CRP: shows whether kinase blockade lowers systemic inflammation.
  • Comprehensive Metabolic Panel: liver enzymes, since fatty liver was an outcome studied.

TBK1 and IKK-epsilon inhibition raises cAMP and energy expenditure; those kinases also run antiviral innate immunity. PMID 24368730 PMID 35917178

Bloodwork to runHow you would know it is working: 7 tests in one order, code CAMERON

Amlexanox FAQ4 common questions

Is Amlexanox approved for human use?
No. Amlexanox is a research compound.
What is Amlexanox researched for?
Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Which labs show whether it's doing anything?
HbA1c; Insulin; hs-CRP; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Amlexanox: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Amlexanox is. Skool covers how it is run.

Free on this page

What Amlexanox is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Amlexanox is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool